Blue Chip Pharma Stock: Rs. 10.50 Dividend, February 06 - Record Date; A Dose of Growth?

A global pharmaceutical corporation based in India, Sun Pharmaceutical Industries Limited (Sun Pharma) produces and markets generic drugs. It is among the largest generic pharmaceutical firms in the world and the largest in India. Sun Pharma produces and markets active pharmaceutical ingredients (APIs) and pharmaceutical formulations. It is India's largest pharmaceutical corporation. It is rated second by prescriptions in the generic dermatological industry and is one of the top generic pharmaceutical businesses in the United States.

Sun Pharma Dividend

The Board of Directors "Declared an interim dividend of Rs. 10.50/- (Rupees Ten and Paise Fifty only) per equity share of Re. 1/- (Rupee one only) each of the Company for the financial year 2024-25. As intimated on January 16, 2025, the Record Date for entitlement of interim dividend for the financial year 2024-25 is February 06, 2025. The interim dividend shall be paid on or before February 20, 2025," said the company in a stock exchange filing.

Sun Pharma Q3 Financials

For the third quarter of the current fiscal year (Q3FY25), Sun Pharmaceutical Industries reported a 15% year-on-year (Y-o-Y) growth in its consolidated net profit at Rs 2,903.3 crore, while its revenue from operations climbed by 10.5% to Rs 13,675.4 crore. The company's earnings before interest, tax, depreciation, and amortisation (EBITDA) boosted by 25% to Rs 4,192 crore from Rs 3,353 crore reported in Q3FY24.

Sun Pharma Share Price Target

Mandar Bhojane - Equity Research Analyst at Choice Broking said, "SUNPHARMA is currently trading at ₹1,738, moving within a consolidation range of ₹1,700-₹1,800, indicating a neutral to bearish sentiment. The stock is holding above its 200-day Exponential Moving Average (EMA), suggesting that this level is acting as a Major support. However, with the Relative Strength Index (RSI) at 41.38 and trading in a flat manner, momentum remains weak, reinforcing the ongoing sideways trend."

"If the bearish sentiment persists, the stock may test the key support zone between ₹1,635 and ₹1,680. This level could provide a potential buying opportunity if bullish reversal signals emerge. On the upside, if SUNPHARMA sustains above ₹1,800 and shows strength with increasing volume, it may indicate a trend reversal. In such a case, a potential rally towards ₹1,895-₹1,960 could unfold, making it an attractive entry point for traders," the analyst added.

"To manage risk effectively, a stop-loss near ₹1,700 would be advisable to protect against further downside. Given the current consolidation phase, traders should closely monitor price action around key levels before taking positions. A decisive breakout on either side will provide clarity on the next significant move for the stock," Mandar Bhojane recommended.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.